Forecast

The analysts' average price target is +111,66€ (+1,79%). The median is +111,60€ (+1,73%).

Buy	23
Hold	20
Sell	1

News Go to news feed

Incyte receives EU approval for Opzelura to treat moderate atopic dermatitis

The European Commission has approved Opzelura (ruxolitinib) from Incyte for topical treatment of moderate atopic dermatitis in adults when corticosteroids and calcineurin inhibitors are unsuitable or ineffective. The approval is based on phase‑3 data, notably the TRuE‑AD4 study with 241 patients, in which Opzelura showed significant improvements in EASI‑75 and IGA‑TS after eight weeks and achieved high success rates after 24 weeks of 84.3% (EASI‑75) and 70.6% (IGA‑TS). Common adverse events were upper respiratory tract infections and nasopharyngitis; serious infections, cardiovascular events, malignancies, or thromboses were not reported during the 24‑week observation period. » More on de.investing.com
Incyte reaches 52-week high of 119.60 USD

Incyte shares rose to a new 52-week high of 119.60 USD and gained 68.7% over the past year. Market capitalization is 23.74 billion USD, the P/E ratio is 16.68 and revenue growth over the last twelve months is 21.48%. Incyte also signed a global licensing agreement with Halozyme for subcutaneous development of INCA033989, is preparing data presentations for the ESMO Congress 2026, and received positive analyst reactions including a buy rating from H.C. Wainwright (price target 140 USD). BMO raised its price target to 112 USD after strong Opzelura revenue forecasts for Q2 2026. » More on de.investing.com
Incyte to present data on six oncology programs at ESMO 2026

Incyte will present data from six oncology programs at the ESMO 2026 congress, including phase‑1 results for INCB161734 (oral KRAS‑G12D inhibitor) and INCA33890 (bispecific TGFβR2×PD‑1 antibody). The company will feature four rapid oral presentations and two posters, including final survival data from the phase‑3 POD1UM‑303/InterAACT‑2 study on retifanlimab and data on INCB123667 in combination with bevacizumab. The first two agents are also being investigated in parallel phase‑3 programs as first‑line therapies for pancreatic cancer and microsatellite‑stable colorectal cancer, respectively. The announcement highlights a robust pipeline; the stock is trading near its 52‑week high, and the company is reported to have solid revenue growth and a strong balance sheet. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Incyte Co. has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, Incyte Co. had revenue of 1.47b€ and net profit of 513.11m€

(EUR)	Jun 2026	YoY
Revenue	+1.47b	42,23%
Gross profit	+1.37b	42,56%
Net profit	+513.11m	49,33%
EBITDA	+658.99m	33,57%

Fundamentals

Metric	Value
Market capitalization	+22.71b€
Number of shares	202.70m
52-week high/low	+113,83€ - +69,61€
Dividends	No
Beta	0,77
P/E ratio	+16,05
PEG ratio	+0,20
P/B ratio	+4,12
P/S ratio	+4,54

Company profile

Incyte Corporation, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung eigener Therapeutika in den Vereinigten Staaten und international. Das Unternehmen bietet JAKAFI, ein Medikament zur Behandlung von Myelofibrose und Polycythemia vera, PEMAZYRE, einen Fibroblasten-Wachstumsfaktor-Rezeptor-Kinase-Inhibitor, der als onkogener Treiber in verschiedenen flüssigen und festen Tumorarten wirkt, und ICLUSIG, einen Kinase-Inhibitor zur Behandlung von chronisch-myeloischer Leukämie und Philadelphia-Chromosom-positiver akuter lymphoblastischer Leukämie. Zu den Produkten in der klinischen Phase gehören Ruxolitinib, ein steroidrefraktäres Medikament gegen chronische Transplantat-gegen-Wirt-Krankheiten (GVHD); Itacitinib, das sich in der klinischen Phase II/III zur Behandlung der naiven chronischen GVHD befindet; und Pemigatinib zur Behandlung von Blasenkrebs, Cholangiokarzinom, myeloproliferativem Syndrom und Tumoragnostik. Darüber hinaus entwickelt das Unternehmen Parsaclisib, das sich in einer klinischen Phase-II-Studie für follikuläre Lymphome, Marginalzonen-Lymphome und Mantelzell-Lymphome befindet. Darüber hinaus entwickelt es Retifanlimab, das sich in klinischen Phase-II-Studien für MSI-hochgradigen Endometriumkrebs, Merkelzellkarzinom und Analkrebs sowie in klinischen Phase-II-Studien für Patienten mit nicht-kleinzelligem Lungenkrebs befindet. Das Unternehmen hat Kooperationsvereinbarungen mit Novartis International Pharmaceutical Ltd; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc; Merus N.V.; Syros Pharmaceuticals, Inc; Innovent Biologics, Inc; Zai Lab Limited; Cellenkos, Inc.und Nimble Therapeutics, sowie klinische Kooperationen mit MorphoSys AG und Xencor, Inc. zur Untersuchung der Kombination von Tafasitamab, Plamotamab und Lenalidomid bei Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom und rezidiviertem oder refraktärem follikulärem Lymphom. Das Unternehmen wurde 1991 gegründet und hat seinen Hauptsitz in Wilmington, Delaware.